Identification
Personal identification
- Full name
- Sandra Catarina da Conceição Alves
Citation names
- Alves, Sandra
Author identifiers
- Ciência ID
- B618-7244-EEE2
- ORCID iD
- 0000-0002-8881-9197
Websites
Knowledge fields
- Medical and Health Sciences - Basic Medicine - Human Genetics
Languages
Language | Speaking | Reading | Writing | Listening | Peer-review |
---|---|---|---|---|---|
English | Upper intermediate (B2) | Advanced (C1) | Advanced (C1) | Advanced (C1) | Advanced (C1) |
Education
Degree | Classification | |
---|---|---|
2002/06/25
Concluded
|
Biology (Doutoramento)
Major in Molecular Biology
Universidade do Porto Faculdade de Ciências, Portugal
"Genetic Characterisation of the Drug metabolising enzymes Thiopurine S-methyltransferase, Glutathione S-transferase mu-1
and Glutathione S-transferase theta-1 in the Northern Portuguese Population " (THESIS/DISSERTATION)
|
|
1997
Concluded
|
Human Genetics (Mestrado)
Universidade do Porto Faculdade de Ciências, Portugal
"Thiopurine methyltransferase: molecular study in North Portugal " (THESIS/DISSERTATION)
|
|
1991 - 1995
Concluded
|
Biology degree (Licenciatura)
Universidade do Porto Faculdade de Ciências, Portugal
"n/a" (THESIS/DISSERTATION)
|
Affiliation
Science
Category Host institution |
Employer | |
---|---|---|
2004/06/22 - Current | Auxiliary Researcher (Research) | Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal |
Teaching in Higher Education
Category Host institution |
Employer | |
---|---|---|
2006/01/01 - 2009/12/01 | Invited Adjunct Teacher (Polytechnic Teacher) | Instituto Politécnico do Porto Escola Superior de Saúde, Portugal |
2002/09/01 - 2004/06/18 | Adjunct Teacher (Polytechnic Teacher) | Escola Superior de Saúde Jean Piaget Nordeste, Portugal |
Others
Category Host institution |
Employer | |
---|---|---|
2021/01 - Current | Coordination of the Portuguese Mirror Group - European Join Programme on Rare Diseases | Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal |
2020 - Current | Participation in SARS-CoV-2 molecular genetics tests | Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal |
2020 - Current | Member of Executive Committee of Center for the Study of Animal Science (CECA) and LA AL4AnimalS | Universidade do Porto Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares, Portugal |
Universidade do Porto Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares, Portugal | ||
2010/01/01 - Current | Staff Scientist (Auxiliary Researcher) and Head of the Lysosomal Storage Diseases Research Group-Department of Human Genetics | Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal |
2002/07/01 - 2004/06/18 | Pos-Doc Student | Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal |
1998/01/01 - 2002/06/25 | PhD Student | Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal |
1995/10/01 - 1997/12/03 | Master Student | Universidade do Porto Faculdade de Ciências, Portugal |
Projects
Grant
Designation | Funders | |
---|---|---|
2017 - Current | RNA-based therapies for Mucopolysaccharidoses
SFRH/BD/124372/2016
Supervisor
Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal
|
Fundação para a Ciência e a Tecnologia, I.P. |
2023/01/01 - 2026/12/31 | Innovative & personalized RNA-based therapies for rare diseases and development of models for their testing: application to
Mucolipidosis II
2022.13676.BD
Supervisor
Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
Universidade do Porto Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares, Portugal |
Fundação para a Ciência e a Tecnologia
Ongoing
|
2015 - 2019 | Less is more - Substrate Reduction Therapy for Mucopolysaccharidoses through RNAi
SFRH/BPD/101965/2014
Supervisor
Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2016/01 - 2018/12 | Application of splicing approaches to exploit alternative therapies for Lysosomal Storage Diseases: in vitro and in vivo studies | Fundação para a Ciência e a Tecnologia, I.P.
Concluded
|
2010 - 2015 | SPLICING THERAPEUTICS FOR PATIENTS AFFECTED BY LYSOSOMAL STORAGE DISORDERS
SFRH/BD/64592/2009
Supervisor
Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal
|
Fundação para a Ciência e a Tecnologia, I.P.
Concluded
|
2009 - 2013 | Molecular, biochemical, and functional studies in genes determining missorting of lysosomal proteins
SFRH/BD/48103/2008
Supervisor
|
Fundação para a Ciência e a Tecnologia
Concluded
|
Contract
Designation | Funders | |
---|---|---|
2024/09 - Current | European Rare Diseases Research Alliance (ERDERA)
101156595
Researcher
|
European Commission |
2023/03/01 - 2024/09/30 | New models for the most frequent Mucolipidosis II-causing mutation using iPSCs and zebrafish: a crucial step towards the development
of new therapies
2022.03836.PTDC
Researcher
Universidade do Porto Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares, Portugal
|
Fundação para a Ciência e a Tecnologia, I.P.
Ongoing
|
2023/03/01 - 2024/09/30 | Development of a Genetic Substrate Reduction Therapy for MPS III using Antisense Oligonucleotides as therapeutic agents (ASOs2cureMPSIII)
2022.04667.PTDC
Principal investigator
Universidade do Porto Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares, Portugal
|
Fundação para a Ciência e a Tecnologia, I.P.
Ongoing
|
2019/01/01 - 2024/08/31 | European Joint Programme on Rare Diseases (EJP_RD). EJP RD 825575. EU Framework Programme Horizon 2020
Researcher
|
Horizon 2020
Ongoing
|
2023 - 2024 | Addressing a challenging enzyme in vitro: proof of principle on the therapeutic potential of an antisense oligonucleotide
approach for Mucolipidosis II
NA
Co-Principal Investigator (Co-PI)
|
Universidade de Lisboa Faculdade de Medicina Veterinária
Ongoing
|
2022/01/01 - 2023/12/31 | Neurological disease modeling for Mucopolysaccharidosis type III: a key step towards understanding and treating a rare genetic
disorders
EXPL/BTM-SAL/0659/2021
Researcher
Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
|
Fundação para a Ciência e a Tecnologia |
2022/01/01 - 2023/12/31 | RNA-Seq based methods to identify novel disease biomarkers in neurodegenerative metabolic diseases
Researcher
Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
|
Fundação para a Ciência e a Tecnologia |
2021/05/01 - 2023/04/30 | Skipping the Pathology in Rare Diseases: Antisense exon-skipping therapy for Mucolipidosis type II
2020DGH1834
Principal investigator
Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal
|
Sociedade Portuguesa de Doenças Metabólicas - Portuguese Society of Metabolic Diseases |
2020 - 2023 | Exploring in vivo U1 snRNA splicing modulation as an alternative therapy for MPS IIIC
Researcher
Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
|
National MPS Society |
2018 - 2023 | Cost action CA17103 - Delivery of Antisense RNA Therapeutics
Researcher
|
Horizon 2020
Concluded
|
2020 - 2021 | Genetic Substrate Reduction Therapy for Mucopolysaccharidoses Toward a siRNA-containing nanoparticle targeted to brain cells
2019DGH1656/SCF2019I&D
Researcher
Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal
|
Sanfilippo Children's Foundation
Ongoing
|
2016/05/01 - 2020/01/31 | Cellular models for the study of lysosomal dysfunction and correction mechanisms
PTDC/BIM-MEC/4762/2014
Researcher
Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal Universidade do Algarve, Portugal |
Fundação para a Ciência e a Tecnologia
Concluded
|
2017 - 2020 | Development of an antisense-mediated exon skipping approach as a therapeutic option for the ML II-causing mutation c.3503_3504delTC
Skip 19
Principal investigator
Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal
|
Asociación Nour de Mucolipidosis
Concluded
|
2016/05/01 - 2019/12/31 | Application of splicing approaches to exploit alternative therapies for Lysosomal Storage Diseases: in vitro and in vivo studies
PTDC/BBB-BMD/6301/2014
Principal investigator
Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
Universidade de Trás-os-Montes e Alto Douro, Portugal |
Fundação para a Ciência e a Tecnologia
Concluded
|
2016 - 2018 | DESVENDAR - DEScobrir, VENcer as Doenças rARas. NORTE-01-0246-FEDER- 000014
NORTE-01-0246-FEDER- 000014
Researcher
Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal
|
Norte 2020
Concluded
|
2014 - 2017 | Less is more - Substrate Reduction Therapy for Mucopolysaccharidoses through RNAi
bcp/LIM/DGH/2014
Principal investigator
Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal
|
Fundação Millenium bcp |
2013 - 2017 | Cost action BM1207 – Networking towards application of antisensemediated exon skipping
Cost action BM1207
Researcher
|
European Commission Seventh Framework Programme for Research and Technological Development |
2010/04/01 - 2013/12/31 | The sorting and trafficking of lysosomal proteins through M6P independent pathways: molecular, biochemical and functional
studies
Principal investigator
Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
Associação para a Investigação e Desenvolvimento da Faculdade de Medicina, Portugal |
Fundação para a Ciência e a Tecnologia
Concluded
|
2008/06/01 - 2011/12/31 | Genetic and non-genetic factors contributing for phenylketonuria phenotype diversity: a study based on the Portuguese Neonatal
Screening Program
Researcher
Universidade do Porto Faculdade de Medicina, Portugal
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal Centro de Genética Médica Doutor Jacinto Magalhães, Portugal |
Fundação para a Ciência e a Tecnologia
Concluded
|
2009/01/01 - 2011/09/28 | Molecular analysis of the Mucolipidosis II and III in Portugal: characterization of the mutational spectrum and relationship
with clinical phenotypes
Principal investigator
Centro de Genética Médica Doutor Jacinto Magalhães, Portugal
Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal |
Fundação para a Ciência e a Tecnologia
Concluded
|
2008/02 - 2009/01 | Molecular screening of Mucopolysaccharidosis type II in Portugal: characterization of the mutational spectrum and relationship
with clinical phenotypes
Project nº 99/2007
Principal investigator
Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal
|
Portuguese Ministry of Health |
2008/02 - 2009/01 | Molecular analysis of Mucopolysaccharidoses type IIIA and IIIB in Portugal characterization of the mutational spectrum and
relationship with clinical phenotype
Project nº 100/2007
Principal investigator
Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal
|
Portuguese Ministry of Health |
2005/09/01 - 2008/08/31 | Neuronal Ceroid Lipofuscinosis: Molecular, biochemical and functional studies
Researcher
Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
Centro de Genética Médica Doutor Jacinto Magalhães, Portugal |
Fundação para a Ciência e a Tecnologia
Concluded
|
2002 - 2005 | Childhood acute lymphoblastic leukemia treatment and susceptibility: influence from genetic factors of detoxifying enzymes
Researcher
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
1997 - 1999 | "Biochemical and molecular genetics of Thiopurine methyltransferase (TPMT, E.C .2.1.1.67)"
PRAXIS/PC NA/BIA/0106/96
Researcher
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
Outputs
Publications
Book chapter |
|
Conference abstract |
|
Conference paper |
|
Journal article |
|
Newsletter article |
|
Report |
|
Thesis / Dissertation |
|
Activities
Oral presentation
Presentation title | Event name Host (Event location) |
|
---|---|---|
2023/10 | Sandra Alves and Paulo Gaspar. Personalized Medicine: situation at national level. 4th edition MPS 360 (Mucopolysaccharidosis 360). Porto, Portugal. October 2023. | |
2023/03 | Sandra Alves. Presentation of the Thematic Line "Inherited metabolic diseases in humans and animals: mechanisms and therapies". VI CECA Meeting. Porto, Portugal. March 2023. | |
2023/02 | Sandra Alves. Antisense Oligonucleotides for Lisosomal Storage Diseases. Final meeting of the Cost Action CA17103 (Delivery of antisense RNA Therapies - DARTER). Bilbao, Spain. February 2023. | |
2022/11 | Sandra Alves. Gene variants, the unfolded protein response, and endoplasmic reticulum stress in a storage disease. Global Symposium on Lysosomal Disorders (GSLSD) 2022. Frankfurt, Germany. November 2022. | |
2022/06 | Sandra Alves. Next generation sequencing and lysosomal dysfunction: novel mutations associated with lysosomal storage disorders. IX Symposium Rare Diseases Common Symptoms. Porto, Portugal. June 2022. | |
2022/05 | Sandra Alves. Development of RNA Therapies and their in vitro and in vivo Experimentation Models. 1st Meeting AL4AnimalS. Lisbon, Portugal. May 2022. | |
2021/10 | Francisca Coutinho, Liliana Matos, Juliana Santos, Mariana Gonçalves, Paulo Gaspar, Sandra Alves. Targeting RNA - Development of Antisense Oligonucleotide-Based Therapies for Lysosomal Storage Diseases. 2nd edition MPS 360 (Mucopolysaccharidosis 360). Porto, Portugal. October de 2021. | |
2021/09 | Sandra Alves. European Joint Programme on Rare Diseases. National Health Institute Dr. Ricardo Jorge Seminar. Online. September 2021. | |
2021/09 | Sandra Alves "Skipping the Pathology in Rare Diseases: Antisense exon-skipping therapy for Mucolipidosis type II". 17th International SPDM Symposium. Fátima, Portugal. September 2021. | |
2021/06 | Sandra Alves Oligonucleotide-based therapies for inherited metabolic diseases: some examples of their application in Lysosomal Storage Disorders. | 23th European Study Group on Lysosomal Diseases Workshop & Graduate Course
European Study Group on Lysosomal Diseases (Online)
|
2021/02 | Sandra Alves. European Joint Programme on Rare Diseases - programme overview and activities. Talk. Rare Disease Day 2021 - Somos muitos; Somos raros; Somos fortes e estamos orgulhosos. Instituto Nacional de Saúde Doutor Ricardo Jorge. February of 2021. Online event. | |
2021/02 | Sandra Alves. Development of RNA therapeutics for Lysosomal Storage Diseases.Talk. BioMeet SESSIONS 2021 on Therapeutic innovation for rare diseases (Inovação Terapêutica nas Doenças Raras). P-BIO. Online event. | |
2021 | Sandra Alves, Francisca Coutinho. Research in Sanfilippo and the Tooth Fairy project. Workshop "Let's talk about Sanfilippo”, 15-16 May 2021 (online). Organization: Sanfilippo Portugal. | |
2020/11 | Sandra Alves. RNA therapeutic approaches: applications to the treatment of Neurological Diseases. Talk. Meeting of the Grupo de Estudos de Envelhecimento Cerebral e Demência (Brain Aging and Dementia Study Group) - Portuguese Society of Neurology. September 2020. Online event. | |
2019 | Alves S. Models to study therapeutic RNA-based molecules for lysosomal storage diseases and to deliver them. Talk. Meeting of the Cost action CA17103 dedicated to antisense oligonucleotides delivery. Munich (Germany). October 2019. | |
2019 | Alves S. The use of antisense oligonucleotides in neurodegenerative diseases. Talk. Meeting of the Portuguese Society of Neurology. Coimbra (Portugal). November 2019. | |
2019 | Sandra Alves. Mucopolysaccharidoses: From the mutation to the Patient. Talk. MPS 360 Event . September 2019. Porto, Portugal. | |
2019 | Sandra Alves. Next generation sequencing and lysosomal dysfunction - novel mutations associated with lysosomal storage disorders. Talk. Workshop on lysosome biology. Lysocil project. CEDOC. September 2019. Lisbon, Portugal. | |
2018 | Sandra Alves. A look over Mucopolysaccharidosis research in Portugal. Talk. First meeting of the Portuguese patients with mucopolysaccharidoses. March 2018. Porto, Portugal. | |
2018 | Sandra Alves. Exon-skipping approaches for rare diseases: application to Neurofibromatosis. Talk. 11th Meeting of the Portuguese Association of Neurofibromatosis (APNF). May 2018, Lisbon, Portugal | |
2018 | Sandra Alves. Lysosomal Storage Diseases: general perspective and new approaches for the molecular diagnosis using Next Generation Sequencing. Rare Disease Day. February 2018. Porto, Portugal | |
2017 | Sandra Alves. Lysosomal storage diseases: an overview. Talk. “Around Research”, Event in the scope of the project PTDC/BIM-MEC/4762/2014 CEMOLY- Cell Models for Lysosomal disorders. October 2017. Porto, Portugal. | |
2017 | Sandra Alves. Development of RNA based approaches to exploit alternative therapies for Lysosomal Storage Diseases. Talk. 21st Annual Meeting of the Portuguese Society of Human Genetics (SPGH). November 2017. Lisbon, Portugal. | |
2015 | Alves S. Development of splicing based approaches to exploit alternative therapies for Lysosomal Storage Diseases. Talk. Meeting of the Cost action BM1207 - Networking towards application of antisensemediated exon skipping. March 2015. Porto, Portugal. | |
2014 | Alves S. Lysosomal Storage Diseases: pathophysiology and innovative therapeutic approaches. Talk. III Meeting CECA. ICBAS. September 2014. Porto, Portgal. | |
2014 | Sandra Alves. Lysosomal Storage Diseases: new tools for diagnosis. 2nd Course of Inherited Metabolic Diseases. Instituto Nacional de Saúde Ricardo Jorge. March 2014. Porto, Portugal. |
Supervision
Thesis Title Role |
Degree Subject (Type) Institution / Organization |
|
---|---|---|
2023/10 - Current | Development of a Genetic Substrate Reduction Therapy for MPS III using Antisense Oligonucleotides as therapeutic agents
Supervisor
|
Biomedicina Molecular (Master)
Universidade de Aveiro, Portugal
|
2023/10 - Current | New models for the most frequent Mucolipidosis II-causing mutation using iPSCs and zebrafish: a crucial step towards the development
of new therapies
Co-supervisor
|
Biologia Celular e Molecular (Master)
Universidade do Porto Faculdade de Ciências, Portugal
|
2023/01/01 - Current | Innovative & personalized RNA-based therapies for rare diseases and development of models for their testing: application to
Mucolipidosis II.
Supervisor of Mariana Mendes Gonçalves
|
PhD program in Chemical and Biological Sciences (PhD)
Universidade de Trás-os-Montes e Alto Douro, Portugal
|
2018 - Current | The key to open the neuronal box of Tay Sachs disease variant B1: celular models
Co-supervisor of Diogo Ribeiro
|
PhD in Biomedical Sciences (PhD)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2017 - Current | RNA-based therapies for Mucopolysaccharidoses.
Supervisor of Juliana Santos
|
Biology (PhD)
Universidade do Porto Faculdade de Ciências, Portugal
|
2022/10 - 2023/11 | Molecular, Structural and Functional Studies on Niemann-Pick Type C.
Co-supervisor of Hugo Daniel Sousa David
|
Master in Cell and Molecular Biology (Master)
Universidade do Porto Faculdade de Ciências, Portugal
|
2023/02 - 2023/10 | Doenças Lisossomais de Sobrecarga: do Diagnóstico à Investigação. Programa extraordinário de estágios na administração direta
e indireta do estado - EstágiAP XXI
Supervisor
|
Programa extraordinário de estágios na administração direta e indireta do estado - EstágiAP XXI (Other)
Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
|
2023/03 - 2023/04 | Techniques and tools for the diagnosis and therapeutic development in Lysosomal Storage Diseases. Lab Rotation. Erasmus+
Supervisor
|
Lab Rotation (Master) (Other)
Rheinische Friedrich Wilhelms Universitat Bonn Institut fur Biochemie und Molekularbiologie, Germany
|
2021/10 - 2023/02 | Modeling Lysosomal Storage Disorders in an innovative way: Establishment and Characterization of Stem Cell Cultures from the
Dental Pulp of Mucopolysaccharidoses patients.
Supervisor of Sofia Pereira Carvalho
|
Master in Pharmaceutical Biotechnology (Master)
Universidade de Coimbra Faculdade de Farmácia, Portugal
|
2019 - 2022/03 | In vivo validation of RNA Therapeutic Strategies for Lysosomal Storage Diseases.
Co-supervisor of Mariana Gonçalves
|
Master in Clinical Laboratory Biology (Master)
Universidade de Trás-os-Montes e Alto Douro, Portugal
|
2017 - 2017 | Development of an antisense-mediated exon skipping therapeutic strategy for Mucolipidosis II
Supervisor of Regina Vilela
|
Master in Cell and Molecular Biology (Master)
Universidade do Porto Faculdade de Ciências, Portugal
|
2010 - 2015 | Splicing therapeutics for patients affected by lysosomal storage disorders
Supervisor of Liliana Matos
|
Biology (PhD)
Universidade do Porto Faculdade de Ciências, Portugal
|
2009 - 2013 | Molecular, Biochemical and Functional Studies in Genes Determining Missorting of Lysosomal Proteins
Supervisor of Maria Francisca Coutinho
|
Biology (PhD)
Universidade do Porto Faculdade de Ciências, Portugal
|
2009 - 2009 | Mucolipidoses type II and III: mutational spectrum and correlation with the clinical phenotype
Supervisor of Marisa Encarnação
|
Master in Advanced Methods in Molecular Biology (Master)
Universidade de Aveiro, Portugal
|
2009 - 2009 | Functional analysis of a missense mutation on IDS gene associated to splicing alterations
Supervisor of Liliana Matos
|
Master in Molecular Genetics (Master)
Universidade do Minho, Portugal
|
2008 - 2008 | Molecular characterization of Portuguese patients with pathologies related to the lysosomal multienzymatic complex: Sialidosis
and Galactosialidosis
Supervisor of Maria Francisca Coutinho
|
Biology (Master)
Universidade do Porto Faculdade de Ciências, Portugal
|
2007 - 2007 | Molecular characterization of Mucopolysaccharidoses type IIIA and IIIB in Portugal
Supervisor of Mariana Mangas
|
Master in Cell Biology (Master)
Universidade de Coimbra Faculdade de Ciencias e Tecnologia, Portugal
|
Event organisation
Event name Type of event (Role) |
Institution / Organization | |
---|---|---|
2023/03 - Current | Member of the Organizing Committee of the VI CECA Meeting (Center for the Study of Animal Science) (2023/03) | |
2023/02 - Current | Member of the Organizing Committee of the Rare Disease Day 2023. Online. (2023/02) | |
2022/10 - Current | Member of the Organizing Committee of the Training School "Introduction to Nucleic Acid Therapy" Cost Action CA17103 (DARTER). Porto, Portugal. (https://antisenserna.eu/introduction-to-nucleic-acid-therapy/) (2022/10) | |
2022/09 - Current | Member of the Organizing Committee of the General Assembly of the European Joint Programme on Rare Diseases. Porto, Portugal. (https://www.ejprarediseases.org/ejp-rd-general-assembly-2022-held-in-porto/?utm_source=rss&utm_medium=rss&utm_campaign=ejp-rd-general-assembly-2022-held-in-porto) (2022/09) | |
2022/02 - Current | Member of the Organizing Committee of the Rare Disease Day 2022. Online. (2022/02) | |
2021/12 - Current | Member of the Organizing Committee of the Webinar "Discover the European Joint Program on Rare Diseases: Opportunities and Challenges". National Mirror Group do European Joint Programme on Rare Diseases. Online. December 2021 (https://aicib.pt/2022/03/11/newsletter-do-national-mirror-group-portugues-nmg-p-do-programa-europeu-conjunto-para-as-doencas-raras/) (2021/12) | |
2021/10 - Current | Member of the Organizing Committee of the V CECA Meeting (Center for the Study of Animal Science) (2021/10) | |
2021/07 - Current | Member of the Organizing Committee of the 1st Symposium on Oligonucleotide Technologies and Therapeutics@Portugal – OTP2020”
(https://www.i3s.up.pt/event.php?v=127. Online. July 2021. (2021/07)
Symposium
|
|
2021 - 2021 | Rare Disease Day 2021. Somos muitos; Somos raros; Somos fortes e estamos orgulhosos. Online meeting. (2021/02/28) | Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal |
2020 - 2020 | Member of the Organizing Committee of the Training School - The guide to antisense therapy development, integrated into the European COST Action CA17103 (DARTER). February, 2020. Porto, Portugal. (2020 - 2020) | Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal |
2019 - 2019 | Rare Disease Day. 2019. Porto, Portugal. (2019 - 2019) | Instituto Nacional de Saúde Doutor Ricardo Jorge IP, Portugal |
2017 - 2017 | Meeting of the COST action BM1207 "Networking towards clinical application of antisense-mediated exon skipping". March, 2017.
Porto, Portugal. (2017)
Meeting (Co-organisor)
|
Jury of academic degree
Topic Role |
Candidate name (Type of degree) Institution / Organization |
|
---|---|---|
2020/12 | Development, validation and implementation of an NGS gene panel approach for the diagnosis of primary immunodeficiencies.
Master in Cell and Molecular Biology. Faculty of Sciences. University of Porto. December 2020.
(Thesis) Main arguer
|
Raquel Alexandra Fonseca da Silva (Master)
Universidade do Porto Faculdade de Ciências, Portugal
|
2020/09/23 | Role of Repeat Instability in the Neurodegenerative Disease Spinocerebellar Ataxia Type 37. Master in Biochemistry for Health.
ITQB - University NOVA of Lisbon. September 2020.
(Thesis) Main arguer
|
Rita Isabel dos Santos Ratola (Master)
Universidade Nova de Lisboa Instituto de Tecnologia Química e Biológica, Portugal
|
2016 | Influence of variants in JOSD1, JOSD2 and ATXN3L on Machado-Joseph disease age-at-onset. Master in Bioengineering. Institute
of Biomedical Sciences Abel Salazar (ICBAS)/Faculty of Engineering (FEUP). University of Porto. 2016.
(Thesis) Main arguer
|
Filipe Costa (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
Universidade do Porto Faculdade de Engenharia, Portugal |
2013 | "New targets and therapeutic approaches in inherited metabolic disorders”. PhD in Pharmacy. Faculty of Pharmacy. University
of Lisbon. 2013
(Thesis) Arguer
|
Sandra Dolores Arduim Brasil. (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2013 | A study on Pharmacogenetic polymorphisms in the Portuguese Gypsies”. Master in Forensic Genetics. Faculty of Sciences. University
of Porto. 2013
(Thesis) Main arguer
|
Joana Maria Santiago (Master)
Universidade do Porto Faculdade de Ciências, Portugal
|
2011 | Identification of mutations in the GNPTAB gene in Brazilian Patients with Mucolipidosis type II and III. Faculty of Medicine. Federal University of Rio Grande do Sul. Master in Medical Sciences. 2011. | Gabriela Kampf Cury. (Master)
Universidade Federal do Rio Grande do Sul, Brazil
|
Association member
Society Organization name | Role | |
---|---|---|
2020 - Current | Member of the Scientific Advisory Board of the Patient Organization RD-Portugal (União das Associações das Doenças Raras de Portugal) https://raras.pt/conselho_cientifico/#S | |
2019 - Current | Member of the Inherited Metabolic Diseases Section of the Portuguese Society of Paediatrics (SDHM.SPP) | |
2017 - Current | Member of the Board of the European Study Group on Lysosomal Storage Diseases. | |
2016 - Current | Member of the Scientific Advisory Board of the APL - Portuguese Association of Lysosomal Diseases https://aplisosoma.org/comissao-cientifica-apl/ | |
2012 - Current | Member of the scientific advisory board of the patient organization Jonah's Just Begun-Foundation to Cure Sanfilippo | |
2012 - Current | Member of the scientific advisory board of the patient associations Sanfilippo Portugal. |
Committee member
Activity description Role |
Institution / Organization | |
---|---|---|
2022 - Current | Member of the Executive Committee of the Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS) - LA/P/0059/2020.
Member
|
|
2020 - Current | Member of the Executive Committee of the FCT Research Unit, Centro de Estudos em Ciência Animal (CECA).
Member
|
|
2019/01/01 - Current | Representative of the National Institute of Health Dr. Ricardo Jorge (INSA) and of the Ministry of Health in the European
Joint Programme on Rare Diseases (EJP_RD). EJP RD 825575. EU Framework Programme Horizon 2020 (2019-2022).
Member
|
|
2017 - Current | Member of the Coordinating Committee of the Scientific Council. National Institute of Health Dr. Ricardo Jorge (INSA). Since
2017.
Member
|
|
2013/03/22 - Current | Member of the National Lysosomal Storage Diseases Treatment Commission (Comissão Coordenadora do Tratamento das Doenças Lisossomais
de Sobrecarga (CCTDLS)
Member
|
Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal |
2018 - 2023 | Portuguese delegate in the Management Committee and Core Group Member of the Cost action CA17103 Delivery of Antisense RNA Therapeutics. EU Framework Programme Horizon 2020 (2018-2022). | |
2014 - 2017 | Portuguese delegate in the Management Committee of the Cost action BM1207 – “Networking towards application of antisense mediated
exon skipping”. EU RTD Framework Programme - 7º Framework Programme (2014-2017).
Member
|
Conference scientific committee
Conference name | Conference host | |
---|---|---|
2023/10 - Current | AL4ANIMALS biotech (https://al4animals-biotech.squarespace.com/organization) | AL4Animals |
2020 - Current | 1st Symposium on Oligonucleotide Technologies and Therapeutics@Portugal | I3S |
Course / Discipline taught
Academic session | Degree Subject (Type) | Institution / Organization | |
---|---|---|---|
2021 - Current | Antisense oligonucleotides, agomirs, antagomirs, siRNAs and aptamers: chemical structure and molecular mechanisms of gene expression modulation. Master in Pharmaceutical Biotechnology. Faculty of Pharmacy, University of Coimbra. | Biotecnologia Farmacêutica (Mestrado integrado) | Universidade de Coimbra Faculdade de Farmácia, Portugal |
2020/11 - Current | Lysosomal Storage Diseases: General Perspective and Diagnosis. Seminar. Master in Cell and Molecular Biology. Faculty of Sciences. University of Porto. November 2020, 2021. | Master in Cell and Molecular Biology (Mestrado) | Universidade do Porto Faculdade de Ciências, Portugal |
2020/03 - 2020/03 | RNA Therapies: use of antisense oligonucleotides for the Treatment of LSDs. Seminar. Master in Biochemistry for Health. School of Health (ESS) - Polytechnic Institute of Porto (P. PORTO). March 2020. | Master in Biochemistry for Health (Mestrado) | Instituto Politécnico do Porto Escola Superior de Saúde, Portugal |
Evaluation committee
Activity description Role |
Institution / Organization | Funding entity | |
---|---|---|---|
2021/02 - Current | Coordinator of the 2021 Monitoring Panel, for the evaluation of the final scientific records associated with the funding allocated
to R&D units and Associated Laboratories (Life and Health Sciences domain)
Evaluator
|
Fundação para a Ciência e a Tecnologia, I.P. | |
2020/01 - Current | Coordinator of the 2019/2020 Monitoring Panel, for the evaluation of the final scientific records associated with the funding
allocated to R&D units and Associated Laboratories (Life and Health Sciences domain)
Evaluator
|
Fundação para a Ciência e a Tecnologia, I.P., Portugal | Fundação para a Ciência e a Tecnologia, I.P. |
Journal scientific committee
Journal title (ISSN) | Publisher | |
---|---|---|
2023 - Current | International Journal of Molecular Sciences. Special Issue on “The Lysosome in Human Health and Disease” Guest Editor (1422-0067) | MDPI |
Other jury / evaluation
Activity description | Institution / Organization | |
---|---|---|
2023 - Current | Vaincre Les Maladies Lysosomales (VML). Evaluation of a Research Proposal in the Call 2023 | |
2023 - Current | Fondation Maladies Rares. Evaluation of a Research Proposal in the Call 2023 | |
2022 - Current | AFM theleton (French Muscular Dystrophy Association). Evaluation of a Research Proposal in the Call Trampoline Grants Application/Competition 2021 - 2022. | |
2022 - Current | Fondation Maladies Rares. Evaluation of a Research Proposal in the Call 2022: | |
2020 - Current | Sanfilippo Childrens Foundation (Australia) - Evaluation of a Research Proposal in the 2020 Call | |
2018 - 2023 | Short Training Scientific Missions Coordinator. Cost action CA17103 Delivery of Antisense RNA Therapeutics. EU Framework Programme Horizon 2020 (2018-2022). Responsible for evaluating the STSMs applications. |
Distinctions
Award
2020 | 2020 SPDM Award (Portuguese Society of Metabolic Diseases) |
Other distinction
2023 | Best Poster. Gonçalves M, Matos L, Santos JI, Coutinho MF, Prata MJ, Pires MJ, Oliveira PA, Alves S. An Antisense Oligonucletide based therapy for a rare disease: in vitro and in vivo studies. Young Researcher Day - INSA. Lisbon, Portugal. |
2023 | Best Oral Communication. David H, Ribeiro I, Cardoso MT, Castro Chaves P, Pinhão M, Martins E, Vieira L, Carneiro Silva C, Quelhas D, Platt FM, Ballabio A, Alves S, Encarnação M. Tangled: a tale about NPC1 Protein Trafficking. AL4Animals Thematic Meeting. |
2022 | Best Oral Communication. Santos JI, Gonçalves M, Matos L, Gaspar P, Pires MJ, Oliveira PA, Prata MJ, Coutinho MF, Alves S. RNA as a promising molecule to treat a rare neurodegenerative lysosomal storage disorder. CIISA Congress 2022. Lisbon, Portugal. |
2021 | Best Oral Communication. Santos JI, Gonçalves M, Matos L, Gaspar P, Pires MJ, Oliveira PA, Prata MJ, Coutinho MF, Alves S. Targeted RNA-based therapies for Mucopolysaccharidosis. 17th SPDM International Symposium. Fátima, Portugal. |
2018 | Honourable Mention (oral communication). Matos L, Vilela R, Coutinho MF, Gaspar P, Alves S. Development of an antisense-mediated exon skipping approach as a therapeutic option for the ML II-causing mutation c.3503_3504delTC. |
2018 | Honourable Mention. Project name: Desenvolvimento de uma abordagem terapêutica molecular para a Neurofibromatose tipo 1 através de exon-skipping. |
2017 | Honourable Mention (oral communication). Matos L, Vilela R, Coutinho MF, Gaspar P, Alves S. Development of an antisense-mediated exon skipping approach as a therapeutic option for the ML II-causing mutation c.3503_3504delTC. |
2016 | Best Oral Communication. Matos L, Coutinho F, Duarte J, Santos JI, Amaral O, Alves S. Development of RNA based approaches to exploit alternative therapies for Lysosomal Storage Diseases |
2013 | 2013 SPDM/Genzyme Research Grant/Award. Project name: “Development of a U1snRNA-adapted gene therapeutic strategy to correct 5’ splicing defects in lysosomal storage disorders”. |
2007 | Best Poster. Oliveira E, Gomes V, Quental S, Ferreira F, Alves S, Amorim A, Prata MJ. Pharmacogenetic role of TPMT, ITPA and folate pathway in the treatment of pedriatric acute lymphoblastic leukemia” |
2005 | Best Poster. Oliveira E, Alves S, Quental S, Ferreira F, Norton L, Costa V, Amorim A, Prata MJ. Implicações na terapia da leucemia linfoblástica aguda infantil do polimorfismo genético da tiopurina S-Metiltransferase. |
2003 | Young scientists award (selected poster). Alves S, Amorim A, Rocha J, Prata MJ. Tracing the origin of the most common thiopurine
methyltransferase (TPMT) variants: evidence from the patterns of haplotypic association with two CA repeats.
European Science Foundation, France
|
1998 | Honourable mention. Alves S, Prata MJ, Ferreira F, Amorim A. Polimorfismo Genético da Tiopurina S-Metiltransferase – Caracterização Molecular no Norte de Portugal. |